ArticleCancers2019
Polymorphism in Toll-Like Receptors and
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Toll-like receptors polymorphisms and COVID-19: a systematic review.Molecular and cellular biochemistry · 2025Pooled it
- Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies.BMC cancer · 2023Pooled it
- Common variants in toll-like receptor family genes and risk of gastric cancer: a systematic review and meta-analysis.Frontiers in genetics · 2023Pooled it
- Comprehensive Integration of Genome-Wide Association and Gene Expression Studies Reveals Novel Gene Signatures and Potential Therapeutic Targets forFrontiers in immunology · 2021Pooled it
- Review
- Autoimmune gastritis: emerging insights and clinical management.Nature reviews. Gastroenterology & hepatology · 2026Review
- Multiple gastric tumors in patients with combined autoimmune and helicobacter pylori-associated gastritis: a case report and literature review.Frontiers in immunology · 2025Review
- Toll-like Receptor 4 Signaling Mediates Gastritis and Gastric Cancer.Current molecular medicine · 2025Review
- Unraveling the Mysteries of Autoimmune Gastritis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Review
- Cardiovascular and Neurological Diseases and Association with Helicobacter Pylori Infection-An Overview.Diagnostics (Basel, Switzerland) · 2024Review
- Toll-like receptors in health and disease.MedComm · 2024Review
- Research status and hotspots of autoimmune gastritis: A bibliometric analysis.World journal of gastroenterology · 2023Article
- Article
- The immune microenvironment in gastric adenocarcinoma.Nature reviews. Gastroenterology & hepatology · 2022Review
- Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.RSC medicinal chemistry · 2021Article
- Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.BMC cancer · 2021Article
- Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management.Therapeutic advances in gastroenterology · 2021Review
- Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis.International journal of molecular sciences · 2020Review
- Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Valli De ReImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. vdere@cro.it.
Ombretta RepettoImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. orepetto@cro.it.
Mariangela De ZorziImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. mdezorzi@cro.it.
Mariateresa CasarottoImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. mtcasarotto@cro.it.
Massimo TedeschiImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. massimo.tedeschi@cro.it.
Paolo GiuffridaFirst Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy. paolo.giuffrida01@universitadipavia.it.
Marco Vincenzo LentiFirst Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy. marco.lenti@unipv.it.
Raffaella MagrisGastroenterologia Oncologica Sperimentale, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. raffaella.magris@cro.it.
Gianmaria MioloPreventive Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. gmiolo@cro.it.
Cinzia MazzonSSD Endocrinologia e malattie del metabolismo, Azienda per l'Assistenza Sanitaria 5 Friuli Occidentale, 33170 Pordenone, Italy. cinzia.mazzon@aas5.sanita.fvg.it.
Giorgio ZanetteSSD Endocrinologia e malattie del metabolismo, Azienda per l'Assistenza Sanitaria 5 Friuli Occidentale, 33170 Pordenone, Italy. giorgio.zanette@aas5.sanita.fvg.it.
Lara AlessandriniPathology Dept CRO Aviano, IRCCS, National Cancer Institute, 33081 Aviano, Italy. lara.alessandrini@aopd.veneto.it.
Vincenzo CanzonieriPathology Dept CRO Aviano, IRCCS, National Cancer Institute, 33081 Aviano, Italy. vcanzonieri@cro.it.
Laura CaggiariImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. lcaggiari@cro.it.
Stefania ZanussiImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. szanussi@cro.it.
Agostino SteffanImmunopatologia e Biomarcatori Oncologici/Bio-proteomics facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. asteffan@cro.it.
Antonio Di SabatinoFirst Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy. a.disabatino@smatteo.pv.it.
Renato CannizzaroGastroenterologia Oncologica Sperimentale, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. rcannizzaro@cro.it.
Centro di Riferimento Oncologico · ITUniversity of Pavia · ITAzienda Sanitaria di Firenze · ITUniversity of Trieste · IT
Funding
Centro di Riferimento Onoclogico CRO 5X1000_2010_MdS, Italy
Abstract
Autoimmune atrophic gastritis (AAG) is associated with an increased risk of certain types of gastric cancer (GC).
Indexed as
autoimmune gastritisflagellin AHelicobacter pyloritoll-like receptor 5 (TLR5)toll-like receptor 9 (TLR9)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.